Opthea To Present at SVB Leerink Global Biopharma Conference
February 06, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at Sequire Biotechnology Conference
January 30, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
December 12, 2022 10:08 ET
|
Opthea Limited
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the FLORetina 2022 Congress
December 06, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at Jefferies London Healthcare Conference
November 10, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
October 24, 2022 06:00 ET
|
Opthea Limited
Key appointment as Opthea progresses Phase 3 registrational trials of OPT-302 for wet AMD MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical...
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
August 30, 2022 06:00 ET
|
Opthea Limited
Secured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations...
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 16, 2022 07:46 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Successfully Closes Well Supported US$90 Million Equity Financing
August 14, 2022 21:02 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
August 14, 2022 21:01 ET
|
Opthea Limited
Carlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M,...